Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.3 USD | -0.85% | -3.38% | +2.12% |
May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
May. 22 | Strides Pharma Arm Gets US FDA's Approval for Generic Stomach Ulcer Drug | MT |
Evolution of the average Target Price on AbbVie Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering AbbVie Inc.
Cantor Fitzgerald | |
Daiwa Securities | |
BMO Capital | |
Mizuho Securities | |
Barclays | |
Deutsche Bank Securities | |
UBS | |
Truist Securities | |
Piper Sandler | |
Morningstar | |
Wells Fargo Securities | |
Goldman Sachs | |
Raymond James | |
William Blair & Co. | |
BofA Securities | |
HSBC | |
Morgan Stanley | |
Guggenheim | |
Argus | |
Wolfe Research | |
Atlantic Equities | |
SVB Securities LLC | |
Credit Suisse | |
Societe Generale | |
Berenberg Bank | |
JPMorgan Chase | |
Cowen | |
Redburn | |
SVB Leerink | |
RBC Capital Markets |
EPS Revisions
- Stock Market
- Equities
- ABBV Stock
- Consensus AbbVie Inc.